What it's for (Indications)
- Amodiaquine is primarily indicated for the treatment of uncomplicated Plasmodium falciparum malaria, especially in regions where chloroquine resistance is prevalent.
- It is almost exclusively used as part of an Artemisinin-based Combination Therapy (ACT), typically in combination with artesunate, to enhance efficacy, achieve rapid parasite clearance, and delay the development of drug resistance.
- This combination therapy (artesunate-amodiaquine, ASAQ) is strongly recommended by the World Health Organization (WHO) as a first-line treatment for uncomplicated falciparum malaria in many endemic areas.
- While historically used for malaria chemoprophylaxis, its utility for this purpose is now limited due to the emergence of resistance and potential for adverse effects, although it may still be considered in specific circumstances or regions as part of a combination regimen.
- Its efficacy against chloroquine-sensitive strains of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae has also been noted, but its primary and most significant role remains in the management of P.
- falciparum infections.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the treatment of uncomplicated Plasmodium falciparum malaria, amodiaquine is administered orally, typically as part of a 3-day Artemisinin-based Combination Therapy (ACT) regimen alongside artesunate. The standard cumulative adult dosage for amodiaquine is 25-30 mg base/kg body weight distributed over three days. A common regimen involves administering 10 mg base/kg body weight on day 1 and day 2, followed by 5 mg base/kg body weight on day 3. However, many fixed-dose co-formulations of artesunate-amodiaquine (ASAQ) exist, which simplify dosing for different weight bands and ages, ensuring accurate administration. Pediatric dosing is strictly weight-based, ensuring appropriate therapeutic levels while minimizing adverse effects. Specific dosing schedules and formulations should always adhere to national treatment guidelines and WHO recommendations for malaria management in the specific region. Amodiaquine should generally be taken with food to improve absorption and mitigate potential gastrointestinal upset. It is crucial for patients to complete the entire prescribed course of treatment, even if symptoms resolve, to ensure complete parasite clearance, prevent recrudescence, and minimize the risk of developing drug resistance. |
Safety & Warnings
Common Side Effects
- Patients may experience headache, gastrointestinal (stomach) upset, hair loss, and skin eruptions.
- If these symptoms persist for a long period, medical consultation is advised.
Serious Warnings
- Black Box Warning: Serious Warnings Regarding Amodiaquine Therapy: Amodiaquine treatment is associated with a significant risk of severe and potentially fatal adverse reactions, particularly hepatotoxicity and agranulocytosis. Severe, acute hepatitis, which may be irreversible and lead to liver failure or death, has been reported with amodiaquine use. Patients should be closely monitored for signs and symptoms of liver dysfunction, including but not limited to unexplained nausea, vomiting, abdominal pain, dark urine, or jaundice, and liver function tests (LFTs) should be performed at baseline and periodically thereafter, or as clinically indicated by symptoms. Furthermore, amodiaquine can cause profound hematologic abnormalities, including severe agranulocytosis and neutropenia, which significantly increase the risk of serious, life-threatening infections. Complete blood counts (CBCs) with differential should be performed regularly, especially during prolonged therapy or if symptoms suggestive of myelosuppression (e.g., fever, sore throat, unusual bleeding or bruising) develop. Due to these serious risks, amodiaquine is primarily indicated for the treatment of acute, uncomplicated malaria, often in combination with artemisinin derivatives, and its use for chemoprophylaxis has largely been abandoned in many regions due to an unfavorable risk-benefit profile when used long-term.
- Pregnancy Risk: Pregnancy risk cannot be ruled out; consult a doctor before use.
- Lactation: Should not be used by breastfeeding mothers.
- Driving: Avoid driving as it may affect the ability to drive.
- Alcohol: Avoid consuming alcohol.
- Precautions: Use with extreme caution in patients with porphyrias (a blood disorder), and impaired renal (kidney) or hepatic (liver) function.
- Perform an eye test before and during long-term therapy.
How it Works (Mechanism of Action)
Amodiaquine, a 4-aminoquinoline antimalarial agent chemically related to chloroquine, exerts its parasiticidal effect primarily by interfering with the detoxification of heme within the food vacuole of the malaria parasite (Plasmodium species). During its intraerythrocytic stage, the parasite digests host hemoglobin as a crucial nutrient source. This process releases free heme (ferriprotoporphyrin IX), which is highly toxic to the parasite due to its potent pro-oxidant properties and ability to damage cellular membranes. Under normal circumstances, the parasite protects itself by converting this toxic free heme into an insoluble, non-toxic crystalline pigment called hemozoin through a process known as biocrystallization, mediated by heme polymerase. Amodiaquine, being a lipophilic weak base, readily penetrates the erythrocyte and then accumulates in the parasite's acidic food vacuole, where it becomes protonated and trapped. Within the vacuole, amodiaquine binds to free heme, forming a non-covalent complex that prevents the polymerization of heme into hemozoin. The resultant accumulation of toxic heme-drug complexes disrupts parasite membrane integrity, induces severe oxidative stress, and inhibits essential parasite enzyme systems, ultimately leading to parasite death. This mechanism is analogous to that of chloroquine, but amodiaquine's chemical structure provides some efficacy against certain chloroquine-resistant strains of Plasmodium falciparum, potentially due to differences in parasite efflux mechanisms or drug binding.